Embecta Corp. reported $1.02B of revenue over the trailing twelve months, −7.6% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.02B (to Q3 2026). Net income: $88M, trailing twelve months to Q3 2026. Free cash flow: $165M, trailing twelve months to Q3 2026. Operating margin: 22%, trailing twelve months to Q3 2026.

EMBCEmbecta Corp.

Healthcare

$3.35-66% 1Y

$3.35

$2.8952 weeks$14.20

EMBC as reported

Embecta Corp. reported $1.02B of revenue over the trailing twelve months, −7.6% on the year before. 11 reported series are charted on this page, each one as filed.

$1.02B

Revenue, trailing twelve months · to Q3 2026 · −7.6% against the twelve months before

Net income: $88M
Net income · +4.7% year on year · trailing twelve months to Q3 2026
Free cash flow: $165M
Free cash flow · +24% year on year · trailing twelve months to Q3 2026
Operating margin: 22%
Operating margin · trailing twelve months to Q3 2026

Details›

Every series Ryufin has for EMBC, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.02B	−7.6%	Q3 2026
Net income	$88M	+4.7%	Q3 2026
EPS	$1.47	+3.5%	Q3 2026
Gross margin	59%	n/a	Q3 2026
Operating margin	22%	n/a	Q3 2026
Net margin	8.2%	n/a	Q3 2026
ROE	−17%	n/a	Q3 2026
ROA	9.9%	n/a	Q3 2026
ROIC	37%	n/a	Q3 2026
Free cash flow	$165M	+24%	Q3 2026
P/E	3.92	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.